Irvine, CA (PRWEB) April 29, 2014 Proove Biosciences, the leader in Personalized Pain Medicine testing services, exhibited and presented clinical data on how proprietary genetic tests have been helping physicians improve patient pain treatment outcomes this weekend at The Valley Cancer Pain Foundations Third Annual Cancer Pain Conference. Proove is the only company exhibiting data on how company research and methods have been allowing doctors to utilize genetic analysis to make safer and more effective pain medication selection and dosing. At this weeks session, Proove Clinical Science Liaison, Derrick Holman, MD presented Proove research and provided medical education on the genetics of pain medicine. As the only company presenting data on how genetic tests can improve the efficiency of pain medication and treatment, we were glad to participate in this weekends conference, stated Brian Meshkin, CEO and founder of Proove Biosciences. The Valley Cancer Pain Foundation does a wonderful job of providing an educational opportunity for pain clinicians, anesthesiologists, neurosurgeons, and hospice providers to learn about new technologies and best practices available in treating pain. The annual conference is an industry gathering that aims to promote the most recent and relevant data and treatment options, and provide a forum to … Continue reading →

PUBLIC RELEASE DATE: 30-Apr-2014 Contact: Scott LaFee slafee@ucsd.edu 619-543-6163 University of California - San Diego Numerous studies have suggested a relationship between cardiovascular disease risk factors and prostate cancer. A new study by researchers at the University of California, San Diego School of Medicine, with colleagues in Norway, significantly refines the association, highlighting genetic risk factors associated with low density lipoprotein (LDL) cholesterol and triglycerides as key players and identifying 17 related gene loci that make risk contributions to levels of these blood lipids and to prostate cancer The findings, published in the April 30, 2014 online issue of the International Journal of Epidemiology, provide new insights into the pathobiology of prostate cancer and may point to novel therapies to lower blood lipid levels that might help prevent prostate cancer the second most common cause of cancer death among American men. The research team, headed by senior authors Anders M. Dale, PhD, professor in the departments of radiology, neurosciences and psychiatry at the UC San Diego School of Medicine, and Ole Andreassen, professor of psychiatry at Oslo University, applied a genetic epidemiology method to assess statistics from multiple genome-wide association studies, looking for genetic overlap between the phenotypes for prostate … Continue reading →

By Vanessa Miller, The Gazette Some patients with a suspected genetic disorder will go on what medical professionals call a diagnostic odyssey to find the cause of their symptoms. But those explorations, on occasion, can come up empty, frustrating patients and prompting health care providers to seek outside expertise. Last month, the Iowa Institute of Human Genetics at the University of Iowa began offering such expertise through whole exome sequencing. The genetic test, which analyzes a portion of about 20,000 genes in the human genome in hopes of helping practitioners diagnose and treat a patient, is among several initiatives the institute is pursuing to further personalize medicine for patients in Iowa and across the country. The research we do here is to develop new tests to bring precision medicine to the state, said Colleen Campbell, assistant director of the Iowa Institute of Human Genetics and associate with the UI Department of Otolaryngology. Researchers with the institute also are conducting tests around secondary findings from exome sequencing the discovery of variants in genes unrelated to a patient's primary condition and how a person's genes interact with prescribed medication, including pain medication. The technology is new, but officials with the Iowa institute … Continue reading →

PUBLIC RELEASE DATE: 30-Apr-2014 Contact: Gail Wilson gail.wilson@imperial.ac.uk 44-020-759-46702 Imperial College London A distinctive genetic 'signature' found in the blood of children with tuberculosis (TB) offers new hope for improved diagnosis of the disease. TB is very difficult to diagnose in children and is often recognised late when the child is already critically ill and the disease has spread from the lungs to the brain or other organs. Now an international team of researchers has shown that the disease can be identified in over 80 percent of cases by looking at 51 specific genes in the blood of affected children. The researchers hope the findings published on 30 April in the New England Journal of Medicine could be used to develop a cheap, quick and effective diagnostic test. Lead researcher, Professor Michael Levin, Director of the Wellcome Centre for Clinical Tropical Medicine at Imperial College London, explained: "We urgently need better methods to diagnose TB in children, so treatment can be started earlier and to avoid unnecessary treatment of children who are wrongly diagnosed. The symptoms of TB in children are common to many other childhood diseases, and the standard tests used on adults are not effective in children. Although … Continue reading →

Stem Cell Treatment In Panama Working Wonders This is an update on Beverly after only 10 days in Panama for Stem Cell Treatment. She is feeling so much better and you can see it just by the look on her face. She has Secondary Progressive... By: Stem Cell Patient … Continue reading →

Chaiwat Subprasom/Reuters/Corbis Many companies around the world offer stem-cell treatments to patients with heart disease. An analysis of clinical studies that use adult stem cells to treat heart disease has raised questions about the value of a therapy that many consider inappropriately hyped. Early-phase clinical trials have reported that adult stem cells are effective in treating heart attack and heart failure, and many companies are moving quickly to tap into this potentially lucrative market. But a comprehensive study that looked at discrepancies in trials investigating treatments that use patients own stem cells, published this week in the journal BMJ (ref. 1), finds that only trials containing flaws, such as design or reporting errors, showed positive outcomes. Error-free trials showed no benefit at all. The publication comes as two major clinical trials designed to conclusively test the treatments efficacy are recruiting thousands of patients. The BMJ paper is concerning because the therapeutic approach is already being commercialized, argues stem-cell researcher Paolo Bianco at the Sapienza University of Rome. Premature trials can create unrealistic hopes for patients, and divert resources from the necessary basic studies we need to design more appropriate treatments. Therapies that use adult stem cells typically involve collecting mesenchymal … Continue reading →